Merck KGaA

Latest Headlines

Latest Headlines

Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate

Pharma bigwigs Merck KGaA and Pfizer announced they are collaborating with Dako to develop a companion diagnostic to accompany their investigational immune checkpoint inhibiting candidate in the fight against cancer.

Merck KGaA partner Genea gets CE mark for a pair of IVF technologies

Genea Biomedx partnered its three fertility products in development with Merck KGaA last month. Now it's won a CE mark for two of them: the Gavi automated vitrification instrument and the Geri benchtop incubator.

Merck KGaA's amped-up consumer pitch delivers much-needed sales hike

Sales for Merck KGaA's OTC unit posted a double-digit jump in Q1, and it was no accident. The company has been doubling down on the "consumer" part of "consumer health"--a move it says is paying off.

Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion

Effective branding is important for any company. But it becomes even more important when you share a name with another company--especially when that other company is your rival.

Pfizer, Merck KGaA suit up for Xalkori marketing wave

When Pfizer teamed up with Merck KGaA on lung cancer, the headlines zeroed in on the sexiest part of the $2.85 billion deal: their immuno-oncology plans. The two companies will work together on cancer-fighters in the PD-L1 arena, one of the hottest fields in pharma these days, including a Phase II Merck drug.

Germany's Merck KGaA sees emerging markets as bigger earnings driver than Europe

Germany's Merck KGaA now considers the world's emerging markets as a group, with China a major driver, to be a greater revenue-producer than Europe, unit CEO Bernd Reckmann said in an interview.

Kleiner Perkins' Auxogyn gets $34M to better identify an IVF embryo's odds

Last June, Auxogyn's Eeva System was the first to be cleared by FDA to aid in IVF embryo selection in combination with traditional morphology. Now the startup has raised $34.3 million, out of a planned $41 million, financing round to start commercializing this test, according to an SEC filing.

Merck takes back Japan Erbitux marketing rights, ending BMS arrangement

Merck KGaA said it has taken back Japan marketing rights for its best-selling Erbitux (cetuximab) cancer drug, ending its shared arrangement with Bristol-Myers Squibb effective May 1.

Pfizer-Merck KGaA collaboration could benefit other oncology players with novel delivery tech

Pfizer's partnership with German counterpart Merck KGaA for $850 million upfront, plus as much as $2 billion in milestones, improves the prospects of PD-L1 and PD-1 checkpoint inhibitors in the oncology space, to the excitement of developers of combination therapies to the class of medicines, which feature both biological and mechanical mechanisms.

Merck KGaA to power India plant with coconut and cashew shells

Next year, Merck KGaA plans to start a biomass heating plant in the U.S. but for now is starting on a project in India that will use cashew and coconut shells, recycling a local waste product into biomass fuel.